4 research outputs found

    In vitro Evaluation of Phthalimide Derivatives Against Cancer Cell lines

    Get PDF
    Los cánceres de pulmón, próstata e hígado se encuentran entre los más prevalentes en los hombres. El cáncer de mama, de cuello uterino y de tiroides se encuentran entre los más prevalentes en mujeres (OMS, 2019). El tratamiento del cáncer generalmente incluye quimioterapia y radioterapia; sin embargo, los medicamentos contra el cáncer disponibles tienen una selectividad baja y causan efectos adversos graves, como nefrotoxicidad, neurotoxicidad y mielosupresión (Matsuo et al., 2010). Por tanto, el diseño y desarrollo de compuestos como nuevos agentes anticancerígenos frente a los tipos de cáncer de mayor incidencia son de vital importancia en el campo de la salud. Los derivados de ftalimida son compuestos prometedores para el desarrollo de nuevos agentes anticancerígenos (Li et al., 2011; Grigalius y Petrikaite, 2017; Kamal et al., 2002). Basado en lo anterior, Este trabajo tuvo como objetivo evaluar la actividad antiproliferativa de 43 derivados de ftalimida contra una línea celular de cáncer principal en hombres (HepG2) y dos líneas celulares de cáncer principales en mujeres (HeLa y 4T1). Además, se determinó la citotoxicidad de los compuestos contra una línea celular de fibroblasto murino normal (3T3). Los resultados mostraron que los compuestos C16, E11 y E16 presentaron la mejor actividad antiproliferativa contra las líneas celulares HeLa y 4T1. El compuesto H16 solo disminuyó la proliferación celular en un 32% contra la línea celular HepG2. Los compuestos H5, H16, E2, E16 y C1 no afectaron a la proliferación de la línea celular 3T3. Demostrando que sería importante continuar con el análisis de este tipo de compuestos frente a diferentes cánceres para encontrar nuevos compuestos con mejor actividad que los actualmente disponibles en el mercado

    Ligand-Based Virtual Screening and Molecular Docking of Benzimidazoles as Potential Inhibitors of Triosephosphate Isomerase Identified New Trypanocidal Agents

    Get PDF
    Trypanosoma cruzi (T. cruzi) is a parasite that affects humans and other mammals. T. cruzi depends on glycolysis as a source of adenosine triphosphate (ATP) supply, and triosephosphate isomerase (TIM) plays a key role in this metabolic pathway. This enzyme is an attractive target for the design of new trypanocidal drugs. In this study, a ligand-based virtual screening (LBVS) from the ZINC15 database using benzimidazole as a scaffold was accomplished. Later, a molecular docking on the interface of T. cruzi TIM (TcTIM) was performed and the compounds were grouped by interaction profiles. Subsequently, a selection of compounds was made based on cost and availability for in vitro evaluation against blood trypomastigotes. Finally, the compounds were analyzed by molecular dynamics simulation, and physicochemical and pharmacokinetic properties were determined using SwissADME software. A total of 1604 molecules were obtained as potential TcTIM inhibitors. BP2 and BP5 showed trypanocidal activity with half-maximal lytic concentration (LC50) values of 155.86 and 226.30 µM, respectively. Molecular docking and molecular dynamics simulation analyzes showed a favorable docking score of BP5 compound on TcTIM. Additionally, BP5 showed a low docking score (−5.9 Kcal/mol) on human TIM compared to the control ligand (−7.2 Kcal/mol). Both compounds BP2 and BP5 showed good physicochemical and pharmacokinetic properties as new anti-T. cruzi agents. View Full-Tex

    Unravelling the physicochemical and antimicrobial mechanisms of human serum albumin/tannic acid coatings for medical-grade polycaprolactone scaffolds

    No full text
    Biofilm-related biomaterial infections are notoriously challenging to treat and can lead to chronic infection and persisting inflammation. To date, a large body of research can be reviewed for coatings which potentially prevent bacterial infection while promoting implant integration. Yet only a very small number has been translated from bench to bedside. This study provides an in-depth analysis of the stability, antibacterial mechanism, and biocompatibility of medical grade polycaprolactone (mPCL), coated with human serum albumin (HSA), the most abundant protein in blood plasma, and tannic acid (TA), a natural polyphenol with antibacterial properties. Molecular docking studies demonstrated that HSA and TA interact mainly through hydrogen-bonding, ionic and hydrophobic interactions, leading to smooth and regular assemblies. In vitro bacteria adhesion testing showed that coated scaffolds maintained their antimicrobial properties over 3 days by significantly reducing S. aureus colonization and biofilm formation. Notably, amplitude modulation-frequency modulation (AMFM) based viscoelasticity mapping and transmission electron microscopy (TEM) data suggested that HSA/TA-coatings cause morphological and mechanical changes on the outer cell membrane of S. aureus leading to membrane disruption and cell death while proving non-toxic to human primary cells. These results support this antibiotic-free approach as an effective and biocompatible strategy to prevent biofilm-related biomaterial infections.</p

    In silico evaluation of phenothiazine derivatives as trypanothione reductase inhibitors

    Get PDF
    Background: American trypanosomiasis is caused by parasite Trypanosoma cruzi, and it is considered a worldwide health problem. Current treatment consists of benznidazole and nifurtimox, which are not fully effective against both disease stages and have adverse effects. There is thus a need to find parasite-specific alternative treatments. Search of specific inhibitors of parasite-exclusive crucial enzymes is a known strategy. Trypanothione reductase (TR) enzyme is central in parasite’s redox system both for detoxification of reactive oxygen and nitrogen species as well as amino acid and nucleotide biosynthesis. Phenothiazine scaffold is known by pharmacologists as a very versatile structure and its derivatives have shown TR inhibition. A virtual screening of phenothiazine derivatives from PubChem database may permit finding potential TR inhibitors. Methodology: TR crystal was obtained from the PDB database (1GXF). A total of 100 phenothiazine derivatives complying with Lipinski’s rules were docked in TR active site using AutoDock Vina 1.1.2. Binding energy and interaction profiles, determined with PLIP (Protein-Ligand Interaction Profiler) server, were used to discriminate among derivatives. Results: Binding energy was found to be in the range of -10.9 to -6.1 kcal/mol compared to -8.8 kcal/mol of natural ligand trypanothione disulfide (TS2). Forty-two compounds showed a binding energy greater than or equal to natural ligand, top ten were determined interactions. Main interactions were found with residues important to TS2 binding: Phe396, Leu399, His461, Glu466 and Glu467. Conclusion: Best ranked compounds both by binding energy and interactions may be proposed as TR inhibitors and assayed in vitro to test effectivity
    corecore